



2FW

PATENT

Attorney Docket No.: A-71364/TAL/DHR

Attorney File No.: 465840-00509

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

IYER et al.

Serial No. 10/693,331

Filing Date: October 24, 2003

For: *Cytomodulating Peptides and
Methods for Treating Neurological
Disorders*

Examiner: To Be Assigned

Art Unit: 1644

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Dated: May 18, 2004

Signed: Mari Kleheidam
Mari Kleheidam

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO/SB/8A. In accordance with 1273 Off. Gaz. Pat. Off. 1, 8/5/2003, no copies of U.S. patents and U.S. published applications are enclosed. Copies of all other references are enclosed.

None of the foregoing references are believed to disclose the invention as claimed. Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application.

Serial No.: 10/693,331
Filing Date: October 24, 2003

Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

As far as is known to the undersigned, this Information Disclosure Statement is being filed within three months of the filing date of a national application, within three months of the date of entry of the national state in an international application, or before the mailing date of a first Office Action on the merits as set forth in 37 C.F.R. § 1.97(b), and therefore no fee is required.

While no fee is believed to be due, if this belief is in error, the Commissioner is authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. 465840-00509 (A-71364/TAL/DHR)).


Respectfully submitted,

DORSEY & WHITNEY LLP

Dated: May 09, 2004
Customer Number: 32940
Dorsey & Whitney LLP
Intellectual Property Department
Four Embarcadero Center, Suite 3400
San Francisco, CA 94111-4187
(415) 781-1989 (telephone)
(415) 398-3249 (facsimile)

By: Euk Y. Oh
Euk Y. Oh
Reg. No. 54,345 for
Todd A. Lorenz
Reg. No. 39,754

Attachments: Form PTO/SB/08A, substitute for Form PTO-1449
45 cited references
Return Postcard



Substitute for form 1449A/PTO
(Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/693,331
Filing Date	October 24, 2003
First Named Inventor	IYER, Suhasini
Art Unit	1646
Examiner Name	To Be Assigned
Attorney Docket Number	A-71364/TAL/DHR (465840-00509)

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	5,385,888	01-31-1995	Goodenow et al.	
	A2	5,723,128	03-03-1998	Clayberger et al.	
	A3	5,753,625	05-19-1998	Buelow	
	A4	6,162,434	12-19-2000	Buelow et al.	
	A5	6,288,089	09-11-2001	Zawada et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1	WO 88/05784 A1	08-11-1988	Board of Trustees of Leland Stanford Jr. University		
	B2	WO 90/10016 A1	09-07-1990	The Regents of the University of California		
	B3	WO 93/08817 A1	05-13-1993	Board of Trustees of Leland Stanford Jr. University		
	B4	WO 93/17699 A1	09-16-1993	Board of Trustees of Leland Stanford Jr. University		
	B5	WO 94/02162 A1	02-03-1994	Glycomed, Inc.		
	B6	WO 95/13288 A1	05-18-1995	Board of Trustees of Leland Stanford Jr. University		
	B7	WO 96/22306 A1	07-25-1996	Northern Sydney Area Health Service		
	B8	WO 97/24140 A1	07-10-1997	Board of Trustees of Leland Stanford Jr. University		
	B9	WO 96/35443 A1	11-14-1996	SangStat Medical Corporation		
	B10	WO 97/44052 A1	11-27-1997	Board of Trustees of Leland Stanford Jr. University		
	B11	WO 97/44351 A1	11-27-1997	Board of Trustees of Leland Stanford Jr. University		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	ASHTON, M., et al., "New perspectives in lead generation II: Evaluating molecular diversity," <i>Drug Disc. Today</i> 1(2):71-78 (Feb. 1996).	
	C2	BUELOW, R., et al., "Immunomodulation by soluble HLA class I," <i>Transplantation</i> 59(5):649-654 (Mar. 1995).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/693,331	
			Filing Date	October 24, 2003	
			First Named Inventor	IYER, Suhasini	
			Art Unit	1646	
			Examiner Name	To Be Assigned	
Sheet	2	of	3	Attorney Docket Number	A-71364/TAL/DHR (465840-00509)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C3	CHEN, M., et al., "Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease," <i>Nat. Med.</i> 6(7):797-801 (Jul. 2000).	
	C4	DONG, C., et al., "Defective T-cell differentiation in the absence of <i>Jnk1</i> ," <i>Science</i> 282(5396):2092-2095 (Dec. 1998).	
	C5	DU, Y., et al., "Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease," <i>Proc. Natl. Acad. Sci. USA</i> 98(25):14669-14674 (Dec. 2001).	
	C6	FRIEDLANDER, R.M., et al., "ICE, neuronal apoptosis and neurodegeneration," <i>Cell Death Differ.</i> 5(10):823-831 (Oct. 1998).	
	C7	FRIEDLANDER, R.M., "Apoptosis and caspases in neurodegenerative diseases," <i>N. Engl. J. Med.</i> 348(14):1365-1375 (Apr. 2003).	
	C8	GRASSY, G., et al., "Variable mapping of structure-activity relationships: Application to 17-spirolactone derivatives with mineralocorticoid activity," <i>J. Mol. Graph.</i> 13(6):356-357 (Dec. 1995).	
	C9	HAIECH, J., et al., "Use of TSAR as a new tool to analyze the molecular dynamics trajectories of proteins," <i>J. Mol. Graph.</i> 13(1):46-48 (Feb. 1995).	
	C10	HAN, J., et al., "A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells," <i>Science</i> 265(5173):808-811 (Aug. 1994).	
	C11	HARPER, S., et al., "Signalling for survival and death in neurones," <i>Cell. Signal.</i> 13(5):299-310 (May 2001).	
	C12	IYER, S., et al., "Rational design and development of RDP58," <i>Curr. Pharm. Des.</i> 8(24):2217-2229 (Nov. 2002).	
	C13	JIANG, Y., et al., "Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38 δ ," <i>J. Biol. Chem.</i> 272(48):30122-30128 (Nov. 1997).	
	C14	JIANG, Y., et al., "Characterization of the structure and function of a new mitogen-activated protein kinase (p38 β)," <i>J. Biol. Chem.</i> 271(30):17920-17926 (Jul. 1996).	
	C15	LEE, J., et al., "A protein kinase involved in the regulation of inflammatory cytokine biosynthesis," <i>Nature</i> 372(6508):739-746 (Dec. 1994).	
	C16	LI, Z., et al., "The primary structure of p38 γ : a new member of p38 group of MAP kinases," <i>Biochem Biophys. Res. Commun.</i> 228(2):334-340 (Nov. 1996).	
	C17	LIU, N., et al., "AMPA receptor-mediated toxicity in oligodendrocyte progenitors involves free radical generation and activation of JNK, calpain and caspase 3," <i>J. Neurochem.</i> 82(2):398-409 (Jul. 2002).	
	C18	MANOLIOS, N., et al., "T-cell antigen receptor transmembraned peptides modulate T-cell function and T cell-mediated disease," <i>Nat. Med.</i> 3(1):84-88 (Jan. 1997).	
	C19	PIRVOLA, U., et al., "Rescue of hearing auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation," <i>J. Neurosci.</i> 20(1):43-50 (Jan. 2000).	
	C20	SANCHEZ, R., et al., "Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction," <i>Neurosurgery</i> 48(6):1393-1401 (Jun. 2001).	
	C21	SMALE, G., et al., "Evidence for apoptotic cell death," <i>Exp. Neurol.</i> 133(2):225-230 (Jun. 1995).	
	C22	STEIN, B., et al., "p38-2, a novel mitogen-activated protein kinase with distinct properties," <i>J. Biol. Chem.</i> 272(31):19509-19517 (Aug. 1997).	
	C23	SUN, A., et al., "p38 MAP kinase is activated at early stages in Alzheimer's disease brain," <i>Exp. Neurol.</i> 183(2):394-405 (Oct. 2003).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

<p>Substitute for form 1449A/PTO (Modified)</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>			Complete if Known		
			Application Number	10/693,331	
			Filing Date	October 24, 2003	
			First Named Inventor	IYER, Suhasini	
			Art Unit	1646	
			Examiner Name	To Be Assigned	
Sheet	3	of	3	Attorney Docket Number	A-71364/TAL/DHR (465840-00509)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C24	THELLUNG, S., et al., "P38 MAP kinase mediates the cell death induced by PrP106-126 in the SH-SY5Y neuroblastoma cells," <i>Neurobiol. Dis.</i> 9(1):69-81 (Feb. 2002).	
	C25	THOMAS, L., et al., "DNA end-labeling (TUNEL) in Huntington's disease and other neuropathological conditions," <i>Exp. Neurol.</i> 133(2):265-272 (Jun. 1995).	
	C26	TROOST, D., et al., "Apoptosis in a myotrophic lateral sclerosis is not restricted to motor neurons - Bcl-2 expression is increased in unaffected post-central gyrus," <i>Neuropathol. Appl. Neurobiol.</i> 21(6):498-504 (Dec. 1995).	
	C27	TROY, C.M., et al., "Caspases on the brain," <i>J. Neurosci. Res.</i> 69(2):145-150 (Jul. 2002).	
	C28	WANG, H., et al., "Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase," <i>J. Biol. Chem.</i> 272(38):23668-23674 (Sep. 1997).	
	C29	WILLAIME-MORAWEK, S., et al., "C-Jun N-terminal kinases/c-Jun and p38 pathways cooperate in ceramide-induced neuronal apoptosis," <i>Neuroscience</i> 119(2):387-397 (2003).	
	C30	YASRI, A., et al., "Rational choice of molecular dynamics simulation parameters through the use of the three-dimensional autocorrelation method: application to calmodulin flexibility study," <i>Protein Eng.</i> 9(11):956-976 (Nov. 1996).	
	C31	YRJÄNHEIKKI, J., et al., "A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wider therapeutic window," <i>Proc. Natl. Acad. Sci. USA</i> 96(23):13496-13500 (Nov. 1999).	
	C32	YRJÄNHEIKKI, J., et al., "Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia," <i>Proc. Natl. Acad. Sci. USA</i> 95(26):15769-15774 (Dec. 1998).	
	C33	YUAN, J., et al., "Apoptosis in the nervous system," <i>Nature</i> 417(6805):802-809 (Oct. 2000).	
	C34	ZHU, S., et al., "Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice," <i>Nature</i> 417(6884):74-78 (May 2002).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2